Phaseline

Targets › SLC34A2

SLC34A2 (Sodium-dependent phosphate transport protein 2B): drug programs, companies and trials

2 programs from 2 companies in 3 trials: 3 Phase 1; Oncology; next expected readout Dec 2027.

Involved in actively transporting phosphate into cells via Na(+) cotransport. (UniProt, O95436)

Open in Phaseline: the race on SLC34A2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Gilead SciencesTUB-040
NaPi2b antibody-drug conjugate (ADC)
SLC34A2Phase 1Ovarian CancerDec 2027
Mersana Therapeuticsupifitamab rilsodotin (XMT-1536)
anti-NaPi2b antibody-drug conjugate
SLC34A2Phase 1Platinum Resistant Ovarian Cancer–

Conditions

Ovarian Cancer (2) Platinum Resistant Ovarian Cancer (1)

Modalities

small molecule (1), antibody (1)

Companies

Gilead Sciences (1) Mersana Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.